ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
ADC Therapeutics is implementing a strategic reorganization that includes a 17% global workforce reduction to extend its cash runway into 2028 and generate approximately $10 million in annualized savings. The restructuring aligns resources behind the ZYNLONTA franchise, supporting a planned pre-sBLA meeting with the FDA in August 2026 and a subsequent sBLA submission in the fourth quarter for the LOTIS-5 trial.
Key figures
- Cash runway
- at least into 2028
- One time charges usd
- 3000000
- Annualized savings usd
- 10000000
- Workforce reduction percent
- 17%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.